Targeted α-therapy with 225Ac-PSMA-617 although still preliminary, has demonstrated strong potential to significantly benefit advanced-stage prostate cancer patients. Dr. Machaba Michael Sathekge comments the initial experience with 225Ac-PSMA-617 in a developing country, as one of the first groups to provide this therapy.